medigraphic.com
Federación Mexicana de Ginecología y Obstetricia, A.C.

2012, Number 11

<< Back Next >>

Ginecol Obstet Mex 2012; 80 (11)

Co-expression of estrogen receptors and Her2/ neu in breast cancer. Neoadjuvant chemotherapy, sentinel lymph node and hormonotherapy

López CN, Sánchez MJI, de Santiago GJI

Language: Spanish
References: 13
Page: 720-724
PDF size: 147.89 Kb.


ABSTRACT

Neoadjuvant chemotherapy is an interesting option in the therapy of some breast cancer cases. Cases in which the timing for sentinel lymph node biopsy is controversial. Co-expression of estrogen receptors and Her2/neu (c-erbB-2) in breast cancer may imply hormone resistance, especially to tamoxifen. We present a clinic case with co-expression of estrogen receptors and Her2/neu that was treated with neoadjuvant chemotherapy and previous sentinel lymph node biopsy followed by breast tumorectomy with axillar lymphadenectomy, radiotherapy and hormonotherapy with letrozol, geserelina and trastuzumab. A good treatment response was found.


REFERENCES

  1. Schwartz GF, Lange AK, Topham AK. Breast conservation following induction chemotheraphy for locally advanced carcinoma of the breast (stages IIB and III). Surg Oncol Clin 1995;4:657-669.

  2. Filippakis G, Zografos G. Contraindications of sentinel lymph node biopsy: Are there any really? J Surg Oncol 2007; 5:10.

  3. Schwartz GF, Tannebaum JE, Jernigan AM, Palazzo JP. Axillary sentinel lymph node biopsy after neoadjuvant chemotherapy for carcinoma of the breast. Cancer 2010; 116(5): 1243-51.

  4. Mushawah FA, Tan MC, Margenthaler JA. Axillary staging prior to or after neoadjuvant systemic therapy? A single institutional experience. J Surg Oncol. 2010; 102(5):404-7.

  5. Mauri D, Pavlidis N, Ioannidos JP. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst 2005; 97:188-94.

  6. Charfare H, Limongelli S, Purushotham AD: Neoadjuvant chemotherapy in breast cancer. Br J Surg 2005; 92:14-23.

  7. Schwartz GF, Giuliano AE, Veronesi U, and the Consensus Conference Group: Proceedings of the Consensus Conference on the Role of Sentinel Lymph Node Biopsy in Carcinoma of the Breast. April 19-22, Philadelphia, PA, USA. Breast J2002; 8:126-138.

  8. Ellis MJ, Coop A, Singh B, Mauriac L, Llombe rt-Cuss ac A, Janicke F, Miller WR, Evans DB, Dugan M, Brady C, Quebe- Fehling E, Borgs M. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB- 2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol. 2001; 19 (18):3808-16.

  9. Gago FE, Fanelli MA, Ciocca DR. Co-expression of steroid hormone receptors (estrogen receptor [alpha] and/or progesterone receptors) and Her2/neu (c-erbB-2) in breast cancer: Clinical outcome following tamoxifen-based adjuvant therapy. J Steroid Biochem Mole Biol 2006;98:36-40.

  10. Witters LM, Kumar R, Chinchilli VM, Lipton A. Enhanced anti-proliferative activity of the combination of tamoxifen plus HER-2-neu antibody. Breast Cancer Res Treat 1997;42:1-5.

  11. Kunisue H, Kurebayashi J, Otsuki T, Tang CK, Kurosumi M, Yamamoto S, et al. Anti-HER2 antibody enhances the growth inhibitory effect of anti-oestrogen on breast cancer cells expressing both oestrogen receptors and HER2. Br J Cancer 1999;82:46-51.

  12. Pietras RJ. Interactions between estrogen and growth factor receptors in human breast cancers and the tumor-associated vasculature. Breast Jr 2003;9:361-73.

  13. Abdulkareem IH, Zurmi IB. Review of hormonal treatment of breast cancer. Niger J Clin Pract 2012;15(l):9-14.




2020     |     www.medigraphic.com